SG10201707135RA - Drug combinations - Google Patents

Drug combinations

Info

Publication number: SG10201707135RA
Authority: SG; Singapore
Prior art keywords: drug combinations; drug; combinations
Prior art date: 2013-03-01

Application number

SG10201707135RA

Other languages

English (en)

Inventor

Mohammad Azab

Pietro Taverna

Alessia Covre

Sandra Coral

Original Assignee

Astex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-01

Filing date

2014-02-27

Publication date

2017-10-30

2014-02-27 Application filed by Astex Pharmaceuticals Inc filed Critical Astex Pharmaceuticals Inc

2017-10-30 Publication of SG10201707135RA publication Critical patent/SG10201707135RA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001189—PRAME
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Epidemiology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Dermatology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SG10201707135RA 2013-03-01 2014-02-27 Drug combinations SG10201707135RA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361771525P	2013-03-01	2013-03-01
US201361887165P	2013-10-04	2013-10-04

Publications (1)

Publication Number	Publication Date
SG10201707135RA true SG10201707135RA (en)	2017-10-30

Family

ID=50288308

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201506727RA SG11201506727RA (en)	2013-03-01	2014-02-27	Drug combinations
SG10201707135RA SG10201707135RA (en)	2013-03-01	2014-02-27	Drug combinations

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201506727RA SG11201506727RA (en)	2013-03-01	2014-02-27	Drug combinations

Country Status (24)

Country	Link
US (2)	US20160015805A1 (pl)
EP (2)	EP3563836A1 (pl)
JP (2)	JP6514647B2 (pl)
KR (1)	KR20150125963A (pl)
CN (2)	CN105025884B (pl)
AU (1)	AU2014223348B2 (pl)
CA (1)	CA2902433A1 (pl)
CY (1)	CY1122554T1 (pl)
DK (1)	DK2961388T3 (pl)
ES (1)	ES2734023T3 (pl)
HR (1)	HRP20191171T1 (pl)
HU (1)	HUE044430T2 (pl)
IL (2)	IL240894B (pl)
LT (1)	LT2961388T (pl)
MX (2)	MX366967B (pl)
PH (2)	PH12015501905A1 (pl)
PL (1)	PL2961388T3 (pl)
PT (1)	PT2961388T (pl)
RU (2)	RU2019138702A (pl)
SA (1)	SA515360959B1 (pl)
SG (2)	SG11201506727RA (pl)
SI (1)	SI2961388T1 (pl)
WO (1)	WO2014134355A1 (pl)
ZA (2)	ZA201506150B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
UA116528C2 (uk)	2011-08-30	2018-04-10	Астекс Фармасьютікалз, Інк.	Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
CN114081946A (zh)	2014-03-12	2022-02-25	耶达研究与开发有限公司	降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
US9394365B1 (en)	2014-03-12	2016-07-19	Yeda Research And Development Co., Ltd	Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10519237B2 (en)	2014-03-12	2019-12-31	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en)	2014-03-12	2020-04-14	Yeda Research And Development Co. Ltd	Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
SMT201900544T1 (it)	2014-05-13	2019-11-13	Medimmune Ltd	Anticorpi anti-b7-h1 e anti-ctla-4 per trattare il cancro del polmone non a piccole cellule
CN107072984B (zh) *	2014-07-15	2021-10-01	约翰·霍普金斯大学	源自骨髓的抑制细胞的抑制和免疫检查点阻断
DK3205661T3 (da)	2014-10-07	2021-08-02	Cytlimic Inc	Hsp70-afledt immunitetsinducerende peptid
WO2016061231A1 (en) *	2014-10-14	2016-04-21	Deciphera Pharmaceuticals, Llc	Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
WO2016100851A1 (en)	2014-12-18	2016-06-23	Lankenau Institute For Medical Research	Methods and compositions for the treatment of retinopathy and other ocular diseases
MA41463A (fr)	2015-02-03	2017-12-12	Anaptysbio Inc	Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
CN107428815B (zh)	2015-03-09	2021-07-09	Cytlimic公司	源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
DK3281641T3 (da)	2015-04-07	2021-01-18	Cytlimic Inc	Adjuvans til cancervacciner
CN108024535A (zh) *	2015-07-02	2018-05-11	大塚制药株式会社	冻干药物组合物
WO2018070069A1 (ja)	2016-10-11	2018-04-19	サイトリミック株式会社	医薬
GB201704965D0 (en)	2017-03-28	2017-05-10	Astex Therapeutics Ltd	Pharmaceutical compounds
GB201704966D0 (en) *	2017-03-28	2017-05-10	Astex Therapeutics Ltd	Pharmaceutical compounds
MX2020001233A (es)	2017-08-03	2020-07-20	Otsuka Pharma Co Ltd	Compuesto farmaceutico y metodos de purificacion del mismo.
EP3727374A4 (en) *	2017-12-21	2021-11-10	Merck Patent GmbH	COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
CN108948203B (zh) *	2018-08-09	2019-06-04	南京鼓楼医院	抗pd-1单克隆抗体及其制备方法和应用
EP3725370A1 (en)	2019-04-19	2020-10-21	ImmunoBrain Checkpoint, Inc.	Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
PH12022552820A1 (en) *	2020-04-24	2024-03-25	Genexine Inc	Method for treating cervical cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0627932B1 (en)	1992-11-04	2002-05-08	City Of Hope	Antibody construct
CN1227360C (zh)	1998-02-05	2005-11-16	史密丝克莱恩比彻姆生物有限公司	Mage家族肿瘤相关抗原衍生物及其编码核酸序列
SI2112166T1 (sl)	1998-12-23	2019-05-31	Pfizer Inc.	Človeška monoklonska protitelesa proti CTLA-4
PL203951B1 (pl) *	1999-04-19	2009-11-30	Smithkline Beecham Biolog	Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
GB9908885D0 (en) *	1999-04-19	1999-06-16	Smithkline Beecham Biolog	Vccine
CN1371416B (zh)	1999-08-24	2012-10-10	梅达里克斯公司	人ctla-4抗体及其应用
US6613753B2 (en) *	2001-02-21	2003-09-02	Supergen, Inc.	Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US20030148973A1 (en)	2001-05-23	2003-08-07	Peter Emtage	MAGE-A1 peptides for treating or preventing cancer
WO2003103389A2 (en) *	2002-06-10	2003-12-18	Avax Technologies Inc.	Cryopreservation of haptenized tumor cells
WO2005033278A2 (en)	2003-09-30	2005-04-14	Ludwig Institute For Cancer Research	In vivo efficacy of ny-eso-1 plus iscom
US20050266012A1 (en) *	2004-05-26	2005-12-01	Jean-Marie Andrieu	Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
EP1819735A1 (en)	2004-11-04	2007-08-22	Pfizer Products Inc.	Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
PL1833506T3 (pl)	2004-12-29	2016-01-29	Mannkind Corp	Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych
JP2008526976A (ja) *	2005-01-14	2008-07-24	アバクス・テクノロジーズ・インコーポレーテッド	癌治療用ワクチンの製造方法
EP2418278A3 (en)	2005-05-09	2012-07-04	Ono Pharmaceutical Co., Ltd.	Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko)	2005-07-01	2016-04-05	이. 알. 스퀴부 앤드 선즈, 엘.엘.씨.	예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8715677B2 (en) *	2005-09-01	2014-05-06	Celgene Corporation	Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
US7700567B2 (en) *	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
RU2612521C2 (ru) *	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
EP2456790A1 (en) *	2009-07-20	2012-05-30	Bristol-Myers Squibb Company	Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AU2010305284A1 (en) *	2009-10-06	2012-05-03	Angiochem Inc.	Compositions and methods for the transport of therapeutic agents
GB201006096D0 (en) *	2010-04-13	2010-05-26	Alligator Bioscience Ab	Novel compositions and uses thereof
KR20130096731A (ko)	2010-09-08	2013-08-30	할로자임, 아이엔씨	조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
EP2697256A1 (en) *	2011-04-15	2014-02-19	Compugen Ltd.	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
UA116528C2 (uk) *	2011-08-30	2018-04-10	Астекс Фармасьютікалз, Інк.	Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
EP2958571B1 (en) *	2013-02-21	2024-04-10	Michele Maio	Dna hypomethylating agents for cancer therapy

2014
- 2014-02-27 EP EP19163282.7A patent/EP3563836A1/en not_active Withdrawn
- 2014-02-27 SG SG11201506727RA patent/SG11201506727RA/en unknown
- 2014-02-27 SG SG10201707135RA patent/SG10201707135RA/en unknown
- 2014-02-27 HU HUE14710728 patent/HUE044430T2/hu unknown
- 2014-02-27 RU RU2019138702A patent/RU2019138702A/ru unknown
- 2014-02-27 SI SI201431263T patent/SI2961388T1/sl unknown
- 2014-02-27 CN CN201480011754.5A patent/CN105025884B/zh not_active Expired - Fee Related
- 2014-02-27 RU RU2015141628A patent/RU2708246C2/ru active
- 2014-02-27 US US14/771,011 patent/US20160015805A1/en not_active Abandoned
- 2014-02-27 KR KR1020157025503A patent/KR20150125963A/ko not_active Ceased
- 2014-02-27 LT LTEP14710728.8T patent/LT2961388T/lt unknown
- 2014-02-27 JP JP2015560330A patent/JP6514647B2/ja not_active Expired - Fee Related
- 2014-02-27 WO PCT/US2014/019137 patent/WO2014134355A1/en not_active Ceased
- 2014-02-27 PT PT14710728T patent/PT2961388T/pt unknown
- 2014-02-27 EP EP14710728.8A patent/EP2961388B1/en active Active
- 2014-02-27 DK DK14710728.8T patent/DK2961388T3/da active
- 2014-02-27 CA CA2902433A patent/CA2902433A1/en not_active Abandoned
- 2014-02-27 ES ES14710728T patent/ES2734023T3/es active Active
- 2014-02-27 PL PL14710728T patent/PL2961388T3/pl unknown
- 2014-02-27 AU AU2014223348A patent/AU2014223348B2/en not_active Ceased
- 2014-02-27 MX MX2015011147A patent/MX366967B/es active IP Right Grant
- 2014-02-27 HR HRP20191171TT patent/HRP20191171T1/hr unknown
- 2014-02-27 CN CN201910760009.5A patent/CN110448566A/zh active Pending
2015
- 2015-08-24 ZA ZA201506150A patent/ZA201506150B/en unknown
- 2015-08-27 IL IL240894A patent/IL240894B/en active IP Right Grant
- 2015-08-27 MX MX2019008822A patent/MX2019008822A/es unknown
- 2015-08-28 PH PH12015501905A patent/PH12015501905A1/en unknown
- 2015-08-30 SA SA515360959A patent/SA515360959B1/ar unknown
2019
- 2019-04-12 JP JP2019076111A patent/JP2019142911A/ja active Pending
- 2019-07-10 CY CY20191100738T patent/CY1122554T1/el unknown
- 2019-07-17 US US16/514,377 patent/US20200009247A1/en not_active Abandoned
- 2019-08-16 ZA ZA2019/05426A patent/ZA201905426B/en unknown
- 2019-10-17 PH PH12019550222A patent/PH12019550222A1/en unknown
2020
- 2020-09-15 IL IL277385A patent/IL277385A/en unknown

Also Published As

Publication number	Publication date
MX2019008822A (es)	2019-09-26
SA515360959B1 (ar)	2019-04-03
PT2961388T (pt)	2019-07-11
NZ750690A (en)	2020-09-25
IL277385A (en)	2020-11-30
HRP20191171T1 (hr)	2019-10-04
LT2961388T (lt)	2019-08-26
JP6514647B2 (ja)	2019-05-15
AU2014223348A1 (en)	2015-09-03
MX366967B (es)	2019-07-31
PL2961388T3 (pl)	2019-10-31
PH12015501905A1 (en)	2016-01-11
WO2014134355A1 (en)	2014-09-04
RU2019138702A (ru)	2020-01-27
NZ711757A (en)	2020-09-25
US20200009247A1 (en)	2020-01-09
CA2902433A1 (en)	2014-09-04
US20160015805A1 (en)	2016-01-21
CN105025884A (zh)	2015-11-04
EP2961388A1 (en)	2016-01-06
SI2961388T1 (sl)	2019-10-30
ZA201506150B (en)	2019-11-27
AU2014223348B2 (en)	2018-12-13
ES2734023T3 (es)	2019-12-03
SG11201506727RA (en)	2015-09-29
KR20150125963A (ko)	2015-11-10
EP3563836A1 (en)	2019-11-06
HK1219663A1 (en)	2017-04-13
CN105025884B (zh)	2019-08-20
HUE044430T2 (hu)	2019-10-28
IL240894A0 (en)	2015-10-29
JP2019142911A (ja)	2019-08-29
IL240894B (en)	2020-10-29
MX2015011147A (es)	2016-04-28
RU2015141628A (ru)	2017-04-06
JP2016510030A (ja)	2016-04-04
PH12019550222A1 (en)	2021-10-04
DK2961388T3 (da)	2019-07-08
RU2708246C2 (ru)	2019-12-05
CN110448566A (zh)	2019-11-15
RU2015141628A3 (pl)	2018-03-07
EP2961388B1 (en)	2019-04-24
CY1122554T1 (el)	2021-01-27
ZA201905426B (en)	2022-07-27

Publication	Publication Date	Title
ZA201905426B (en)	2022-07-27	Drug combinations
IL240846A0 (en)	2015-10-29	drug combination
GB201307385D0 (en)	2013-06-05	Syringes
ZA201506252B (en)	2017-06-28	Syringe
GB201308440D0 (en)	2013-06-19	Therapeutic
ZA201600027B (en)	2018-07-25	Pharmaceutical preparation
GB201408677D0 (en)	2014-07-02	Syringes
GB201318668D0 (en)	2013-12-04	Sonosensitive therapeutic
GB201309967D0 (en)	2013-07-17	Therapeutic combinations
GB201310496D0 (en)	2013-07-24	Pharmaceutical combinations
GB201301723D0 (en)	2013-03-20	Pharmaceutical combinations
GB201316662D0 (en)	2013-11-06	Pharmaceutical Combination
GB201320786D0 (en)	2014-01-08	Medicament
ZA201506465B (en)	2021-06-30	Pharmaceutical preparation
AU353327S (en)	2014-01-21	Kettlebell
AU353331S (en)	2014-01-21	Kettlebell
AU353330S (en)	2014-01-21	Kettlebell
AU353329S (en)	2014-01-21	Kettlebell
AU353328S (en)	2014-01-21	Kettlebell
AU353325S (en)	2014-01-21	Kettlebell
AU353326S (en)	2014-01-21	Kettlebell
AP00812S1 (en)	2016-04-13	Stumbelbloc
AU2013231V (en)	2014-06-11	Bonsca7200 Scaevola aemula
AP2013000704S (en)	2016-10-11	Gramoquat
AP2013000606S (en)	2013-05-09	Loftank